MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

MDT

89.1

+0.54%↑

VEEV

283.96

+1.41%↑

A

121.45

+0.27%↑

WBA

11.56

+0.35%↑

HQY

99.61

-3.32%↓

Search

Gossamer Bio Inc

Suletud

SektorTervishoid

1.36 7.94

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.26

Max

1.38

Põhinäitajad

By Trading Economics

Sissetulek

-3.6M

-37M

Müük

510K

9.9M

Kasumimarginaal

-370.492

Töötajad

144

EBITDA

-1.9M

-34M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+588.98% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

8. aug 2025

Turustatistika

By TradingEconomics

Turukapital

34M

284M

Eelmine avamishind

-6.58

Eelmine sulgemishind

1.36

Uudiste sentiment

By Acuity

67%

33%

338 / 376 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Weak Bullish Evidence

Gossamer Bio Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

9. juuli 2025, 15:46 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250 Million Private Placement

9. juuli 2025, 23:44 UTC

Market Talk

Gold Edges Higher Amid U.S. Tariff Concerns -- Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound as U.S. Tariff Uncertainty Continues -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Reliance Worldwide's Costs at Risk From Copper Tariffs -- Market Talk

9. juuli 2025, 22:59 UTC

Market Talk

Global Equities Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 20:26 UTC

Tulu

Nvidia Is the Most Valuable Company Ever. Why $5 Trillion Could Be Next. -- Barrons.com

9. juuli 2025, 19:18 UTC

Market Talk

Oil Futures End Little Changed After Big U.S. Crude Stock Build -- Market Talk

9. juuli 2025, 19:03 UTC

Market Talk

U.S. Natural Gas Posts Back-to-Back Losses -- Market Talk

9. juuli 2025, 18:31 UTC

Market Talk

Some Fed Officials Supported Considering July Cut -- Market Talk

9. juuli 2025, 17:07 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Honeywell's Streamlining Efforts Clear Path for Stock to Catch Up -- Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk -2-

9. juuli 2025, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Health Care Roundup: Market Talk

9. juuli 2025, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

9. juuli 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

9. juuli 2025, 16:14 UTC

Market Talk

Rents in Canada Soften For Ninth-Straight Month -- Market Talk

9. juuli 2025, 16:14 UTC

Omandamised, ülevõtmised, äriostud

Apple Has Dropped the Ball on AI. Buying Perplexity Could Help It Catch Up, Say Analysts. -- Barrons.com

9. juuli 2025, 16:12 UTC

Market Talk

Gold Futures Broadly Flat in Largely Directionless Trade -- Market Talk

9. juuli 2025, 16:08 UTC

Market Talk

Oil Ticks Higher Amid Large U.S. Crude Build, Red Sea Tensions, Tariff Uncertainty -- Market Talk

9. juuli 2025, 15:31 UTC

Suurimad hinnamuutused turgudel

BitMine Shares Fall After Closing of $250M Private Placement

9. juuli 2025, 15:31 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

With Competing Bids Unlikely, Merck's Path to Acquiring Verona Looks Smooth -- Market Talk

9. juuli 2025, 15:27 UTC

Market Talk

Copper Rally Expected to Fade Amid Tepid Global Demand -- Market Talk

9. juuli 2025, 14:36 UTC

Omandamised, ülevõtmised, äriostud

Merck to Buy Verona Pharma in $10 Billion Deal -- 2nd Update

9. juuli 2025, 14:31 UTC

Omandamised, ülevõtmised, äriostud

Meta Has Surged on the Back of AI Software. Why Hardware Is the Next Play. -- Barrons.com

9. juuli 2025, 14:26 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

9. juuli 2025, 14:26 UTC

Market Talk

Aug 1 Tariffs Will Boost Average Rate Near 15%, JPMorgan Estimates -- Market Talk

Võrdlus sarnastega

Hinnamuutus

Gossamer Bio Inc Prognoos

Hinnasiht

By TipRanks

588.98% tõus

12 kuu keskmine prognoos

Keskmine 8.75 USD  588.98%

Kõrge 15 USD

Madal 4 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Gossamer Bio Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

6 ratings

5

Osta

1

Hoia

0

Müü

Tehniline skoor

By Trading Central

1.06 / 1.23Toetus ja vastupanu

Lühikene perspektiiv

Weak Bullish Evidence

Keskpikk perspektiiv

Weak Bearish Evidence

Pikk perspektiiv

Bullish Evidence

Sentiment

By Acuity

338 / 376 Pingereas Tervishoid

Uudiste sentiment

Tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.